TY -的A2 -斯蒂,j . j . AU -巴龙琳达r . AU -波伊尔,斯科特AU - Damewood,詹姆斯·r . AU -杞人忧天,詹姆斯盟——Ciaccio Paul j . PY - 2012 DA - 2012/06/14 TI - Phospholipogenic制药与组织学发现发病率高于Nonphospholipogenic药品在临床前毒理学研究SP - 308594六世- 2012 AB -虽然phospholipidosis被认为是一种适应性反应化学的挑战,许多Phospholipogenic已知化合物显示不良反应在临床前物种和人类。调查phospholipogenic管理和临床发病率之间的联系组织信号,内部阿斯利康 在活的有机体内毒理学报告数据库搜索识别phospholipogenic和nonphospholipogenic化合物。数据集由46 phospholipogenic组装和62 nonphospholipogenic化合物。证实了这些化合物的phospholipogenic潜力病理学家的解释和有效的支持 在网上和 在体外模型。phospholipogenic数据集包含37个基地、4中性化合物,3:既和1酸,而nonphospholipogenic数据集包含9个基地,34中性色,1两性离子,十八酸。为肾上腺组织学研究结果跟踪;骨髓;肾脏;肝;肺;淋巴结;脾;胸腺; and reproductive organs. On average, plasma exposures were higher in animals dosed with the nonphospholipogenics. Phospholipogenics yielded proportionally more histologic changes (exclusive of phospholipidosis itself) in all organs. Statistically significant higher frequencies of liver necrosis, alveolitis/pneumonitis, as well as lymphocytolysis in the thymus, lymph nodes, and spleen occurred in response to phospholipogenics compared to that for nonphospholipogenics. SN - 1687-8191 UR - https://doi.org/10.1155/2012/308594 DO - 10.1155/2012/308594 JF - Journal of Toxicology PB - Hindawi Publishing Corporation KW - ER -